Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
LAT (radiation or surgery) is more important for patients with REO while IO maintenance plays a more dominant role in patients with INO.
This retrospective cohort study explores optimal treatment strategies following immunotherapy failure in metastatic non‑small‑cell lung cancer (NSCLC) by stratifying patients into four oligoprogression patterns (REO, INO, DNP, REP). 500 patients with progression after PD‑1/PD‑L1 inhibitors were included; those with repeat oligoprogression (REO) who received local ablative therapy (LAT) exhibited superior next‑line progression‑free and overall survival, whereas patients with induced oligoprogression (INO) benefited most from continued IO maintenance rather than IO cessation. The findings suggest that therapeutic approaches should be tailored to the specific progression pattern to maximize survival outcomes.
The study highlights that local ablation is preferable for patients with repeat oligoprogression, while immunotherapy maintenance is more beneficial for induced oligoprogression, providing a nuanced, precision‑medicine approach to improve survival after immunotherapy resistance in metastatic NSCLC.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT